Taylor & Francis Group
Browse
iwbp_a_1557345_sm5531.docx (51.61 kB)

The relationship between physical activity, clinical and cognitive characteristics and BDNF mRNA levels in patients with severe mental disorders

Download (51.61 kB)
Version 3 2019-11-11, 15:40
Version 2 2019-01-15, 12:22
Version 1 2018-12-18, 12:25
journal contribution
posted on 2019-11-11, 15:40 authored by Monica Aas, Srdjan Djurovic, Torill Ueland, Ragni H. Mørch, Jannicke Fjæra Laskemoen, Elina J Reponen, Annamaria Cattaneo, Nils Eiel Steen, Ingrid Agartz, Ingrid Melle, Ole A. Andreassen

Background: Here we aimed to clarify the association of physical activity with cognitive function and current mood in severe mental disorders in the most extensive sample to date. Secondly, we aimed to investigate the relationship between physical activity and BDNF mRNA levels.

Methods: Three hundred and six patients with a DSM-IV schizophrenia (SZ) or bipolar disorder (BD) spectrum diagnosis were included. Clinical characteristics were assessed using the Structured Clinical Interview for DSM-IV. Depressive symptomatology was measured using the Inventory of Depressive Symptoms (IDS-C) and the Calgary Depression Scale for Schizophrenia (CDSS). All patients underwent neuropsychological assessment. Physical activity was measured as hours spent on any regular physical activity (≥ or ˂90 min) per week. BDNF mRNA was measured in plasma using standardised procedures.

Results: Patients with ≥90 min of physical activity per week had fewer depressive symptoms (P ˂0.001, Cohen’s d = 0.48) and performed significantly better on working memory (P ˂ 0.001, d = 0.44) and executive functioning tasks (P ˂ 0.001, d = 0.50) compared to the ˂90-min group. BDNF mRNA was positively associated with physical activity (P = 0.046) and cognitive functioning (P = 0.037).

Conclusions: Our study suggests a positive association between self-reported physical activity, cognitive function, mood and BDNF mRNA levels in severe mental disorders.

Funding

This study was funded by grants from the University of Oslo, South-Eastern Norway Health Authority (#2013088, #2017060), the Research Council of Norway (#223273, #248778, #248980), and the KG Jebsen Foundation. This study was also funded by the NARSAD Young Investigator Award (#22388), and the Scandinavian College of Neuropsychopharmacology (SCNP) Young Scientist grant to Monica Aas.

History

Usage metrics

    World Journal of Biological Psychiatry

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC